Every year, insurance plans update the list of drugs that they cover, also known as their formulary. That means that some drugs covered this year won’t be covered next year. (In fact, more and more drugs are excluded from formularies each year.) And drugs that are new to the market might be covered soon. If you rely on health insurance to pay for your medications, now’s a good time to pay attention. See More
Namenda XR Latest News
Get the latest updates on this drug from the GoodRx medical team
The most feared medical condition in folks over 55? Dementia—specifically Alzheimer’s dementia—according to multiple surveys. Cancer is a distant second.
The majority of dementia cases are Alzheimer’s dementia (AD), yet there is currently no easy way to screen for AD. Neuropsychological testing is still the gold standard (this is testing that takes a few hours with a neuropsychologist). Genetic tests are available but only for the rarer early onset form (a small percentage of dementia cases). See More
Studies show that Alzheimer Disease is feared more than any other medical condition in people over 55, even cancer. It’s normal to be concerned if you find your memory is not as good as it used to be as you get older.
You may wonder: is this normal memory loss or do you have Alzheimer Disease (AD)? Are there any tests that can help you find out? There are a few ways to narrow it down.
Neuropsychological testing. See More
There are 8 million new cases of Alzheimer disease (AD) each year—and while new headlines appear every week about potential cures, it may discourage you to know that many recent AD trials have been unsuccessful, though not for a lack of trying. In fact, there have been no new medication approvals for this currently untreatable disease in over ten years.
What about drugs already on the market? Current medications like donepezil (Aricept) and memantine (Namenda) have some benefits for symptoms, but don’t slow progression or prevent the disease. See More
After a long, complicated path, Alzheimers prescription Namenda finally has a generic in the form of memantine. Memantine is now in pharmacies—though for a while it looked like there might never be a generic Namenda at all.
Namzaric (memantine/donepezil) is a new combination drug approved on December 24, 2014 for the treatment of moderate to severe dementia of the Alzheimer type (Alzheimer’s disease) in patients already taking Namenda XR (memantine) and Aricept (donepezil).
What is Alzheimer’s disease?
Alzheimer’s disease involves a decline in mental ability that is severe enough to affect daily activities. It is a progressive disease that follows three stages: mild, moderate, and severe. See More
Effective Friday, August 15, 2014, Namenda (memantine) 5 mg and 10 mg tablets have been discontinued. According to the manufacturer, Forest Laboratories, the discontinuation is not for safety reasons, but because the company is going to be focusing on their once-daily Namenda XR (memantine) capsules.
For people who suffer with 3 – 4 headaches a month and have been refractory or can’t tolerate other therapies, Namenda may be an option.
Last month, I wrote that Namenda was being discontinued by the manufacturer (see the post here), to be replaced with the longer-acting Namenda XR. Forest Laboratories announced its plan to discontinue the sale of Namenda 5mg and 10mg tablets but not because of any safety or efficacy issues, just because they have a longer acting form they want you to use instead.
No more Namenda? Not really, but the shorter-acting form is going away. Forest Laboratories has announced its plan to discontinue the sale of Namenda 5 mg and 10 mg tablets—but not because of any safety or efficacy issues, just because they have a longer-acting form available.
Namenda is an NMDA receptor antagonist approved for the treatment of moderate-to-severe Alzheimer’s dementia. Both the liquid form, Namenda oral solution, and the extended-release capsules, Namenda XR, will continue to be available. See More